TNFSF10 and neoplasm: Moreover, tumour cells are significantly more sensitive to TRAIL-induced apoptosis than normal cells, thus the use of recombinant TRAIL or TRAIL receptor agonistic monoclonal antibodies for selective treatment of CCA in combination with chemotherapeutic drugs may improve patient survival.